[
    [
        {
            "time": "",
            "original_text": "【益丰药房（603939.SH）】不惧高基数影响，业绩增长具有强韧性——2021年一季报点评（林小伟/黄卓）",
            "features": {
                "keywords": [
                    "益丰药房",
                    "高基数",
                    "业绩增长",
                    "强韧性",
                    "2021年一季报"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【益丰药房（603939.SH）】不惧高基数影响，业绩增长具有强韧性——2021年一季报点评（林小伟/黄卓）",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]